drugset / Trial / NCT05350917
Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy
Phase 2
Unknown
20 enrolled
The First Affiliated Hospital of Zhengzhou University
BeiGene · collabJiangsu Hengrui Pharmaceutical Co., Ltd. · collabRemeGen Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will explore the efficacy and safety of tislelizumab (PD1 inhibitor) combined with DisitamabVedotin (ADC) and pyrotinib maleate (TKI) in the treatment of HER2-positive or mutated advanced colorectal cancer who have failed standard therapy .
Timeline
- Start
- 2022-06-20
- Primary completion
- 2025-06-20
- Completion
- 2026-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Disitamab Vedotin | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | Pyrotinib | Small molecule | 320 mg | Oral |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |